Pfizer’s aging Xalkori is the drug to beat in ALK-positive non-small cell lung cancer. After showing Alunbrig cut the risk of disease progression by 51% compared with Xalkori at the two-year mark, Takeda is preparing for regulatory submissions in the
read moreAbbVie has held high hopes for newcomers Skyrizi and Rinvoq as post-Allergan merger business drivers with the ongoing decline of Humira. But with prescription figures and market access tracking way ahead of expectations, did AbbVie know those two meds would
read moreAfter Bristol-Myers Squibb closed its $74 billion Celgene deal this week, investors clamored for a contingent value right (CVR) that’s now trading separately. But the CVR will only pay off if three highly anticipated drugs hit the market, making the
read moreSanofi’s brass are preparing for an investor day in Boston early next month, but its top strategy exec is parting ways ahead of the event. Muzammil Mansuri, executive vice president of strategy and business development since February 2016, is retiring
read moreKorean drugmaker SK Life Science is gearing up for a first launch early next year—provided the DEA cooperates. The company’s seizure drug Xcopri won FDA approval Thursday to treat partial-onset seizures in adults, and all that stands between it and
read moreAmidst a “fire sale” restructuring of bankrupt Insys, the former maker of notorious fentanyl spray Subsys, opioid plaintiffs are still hoping to pick some meat off the drugmaker’s bones. And now, Insys is floating a deal that would come at
read more© 1994 - 2026 B.M. Pharmaceuticals